Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model

Kentaro Miyake,Tasuku Kiyuna,Kei Kawaguchi,Takashi Higuchi,Hiromichi Oshiro,Zhiying Zhang,Sintawat Wangsiricharoen,Sahar Razmjooei,Yunfeng Li,Scott D. Nelson,Takashi Murakami,Yukihiko Hiroshima,Ryusei Matsuyama,Michael Bouvet,Sant P. Chawla,Shree Ram Singh,Itaru Endo,Robert M. Hoffman

Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model

2019

Kentaro Miyake
Tasuku Kiyuna
Kei Kawaguchi
Takashi Higuchi
Hiromichi Oshiro
Zhiying Zhang
Sintawat Wangsiricharoen
Sahar Razmjooei
Yunfeng Li
Scott D. Nelson
Takashi Murakami
Yukihiko Hiroshima
Ryusei Matsuyama
Michael Bouvet
Sant P. Chawla
Shree Ram Singh
Itaru Endo
Robert M. Hoffman

Purpose Ewing’s sarcoma (ES) is a rare and recalcitrant disease which is in need of a development of a novel effective therapy. The aim of this study was to investigate the efficacy of regorafenib on an ES tumor in a patient-derived orthotopic xenograft (PDOX) model.

Keywords:

Pharmacology
Doxorubicin
Regorafenib
Ewing's sarcoma
Cancer research
Sarcoma
Nude mouse
Medicine
untreated control
doxorubicin resistant
Oncology
Right chest
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations